WHY WE WILL NEVER PROMISE YOU INCOME
Federal law, the FTC's Business Opportunity Rule, prohibits unsubstantiated income or earnings claims when offering a business opportunity. Companies are fined for every violation.
Read the rule at FTC.gov →So we do not do fantasy math, and you should sprint from anyone in this space who does. What we can do is show you the publicly reported market data, the demand signals advertisers pay real money against, and let you do your own math. Your results depend on your offer, your effort, and your market.
GLP-1 & WEIGHT LOSS
$100B+ by 2030
Major bank research desks (Goldman Sachs, J.P. Morgan, Morgan Stanley) have publicly projected the global anti-obesity and GLP-1 market at roughly $100 billion or more by 2030. Demand proof: agency benchmarks put GLP-1 and telehealth search clicks at $8 to $25+ each. Advertisers do not pay that for imaginary demand.
HORMONE THERAPY
A reopened category
Public market research houses estimate the menopause and HRT market in the tens of billions globally and growing. After two decades suppressed by a since-lifted warning, professional bodies including NAMS, ACOG, and the Endocrine Society now publicly support HRT as first-line treatment for many patients. Roughly 6,000 US women enter menopause every day, published US census-based estimate.
PEPTIDES
$40B+ and reclassifying
Peptide therapeutics are publicly estimated as a $40B+ global market with projections to roughly double within the decade. The near-term catalyst is regulatory: 12 peptides are moving through the FDA's PCAC review process between 2026 and 2027. First to market wins categories.
TELEHEALTH, THE MACRO
Hundreds of billions
Public research firms project global telehealth in the hundreds of billions of dollars by the early 2030s. Care moved home after 2020 and it is not moving back. The infrastructure to serve hormones, peptides, and labs under one brand is the whitespace.
"WHAT IS YOUR CLIENTS' CPA?" (THE HONEST ANSWER)
Our clients' acquisition costs are confidential, exactly as yours will be when you are the client. What we can share is public benchmark data: GLP-1 and telehealth keywords run $8 to $25+ per click, while hormone-symptom searches (brain fog, night sweats, fatigue) have historically run a fraction of that. Your cost per acquisition will be a function of your offer, your creative, and your market, which is precisely what gets built here. Anyone quoting you a guaranteed CPA before your brand exists is guessing with your money.
SEARCH DEMAND, STRAIGHT FROM GOOGLE
What Americans typed into Google over the last 12 months, and what advertisers pay per click to stand in front of them. Source: Google Keyword Planner, United States, June 2025 to May 2026. This data is available to any advertiser; verify it yourself.
GLP-1 & WEIGHT LOSS
| Search term | Searches / mo | Competition | Top-of-page bid |
|---|
| telehealth weight loss program | 18,100 | Low | $10.74 – $38.22 |
| glp 1 online | 8,100 | High | $23.91 – $60.37 |
| weight loss medication online | 6,600 | High | $16.90 – $49.60 |
| glp 1 weight loss program | 1,300 | Low | $11.94 – $39.35 |
| weight loss injection online | 1,000 | High | $17.38 – $50.88 |
Read: advertisers pay up to $60 for ONE click here. Nobody pays that for imaginary demand. It also means the crowded front door is expensive, which is exactly why the next three tables matter.
BRANDED GLP-1 (NAME-BRAND SEEKERS)
| Search term | Searches / mo | Competition | Top-of-page bid |
|---|
| zepbound covered by insurance | 1,300 | Medium | $8.19 – $23.00 |
| wegovy pill online +1,627% YoY | 1,000 | High | $21.70 – $65.15 |
| wegovy covered by insurance | 720 | Medium | $8.71 – $31.00 |
| zepbound telehealth | 210 | High | $14.46 – $44.26 |
Read: "wegovy pill online" is up 1,627% year over year. Patients are hunting the brand names by name, and brands that carry the branded pathway catch them.
HORMONE THERAPY, WOMEN
| Search term | Searches / mo | Competition | Top-of-page bid |
|---|
| progesterone prescription pills | 1,900 | High | $1.81 – $6.07 |
| progesterone prescription +90% YoY | 1,000 | Medium | $5.81 – $22.61 |
| prescription progesterone cream | 390 | Low | $3.70 – $16.64 |
| prometrium prescription +200% YoY | 50 | Low | $2.91 – $18.89 |
Read: the same patient who costs $24 to $60 a click in the GLP aisle searches her hormone symptoms for a fraction of that. This is the cheaper door to a longer-staying patient.
HORMONE THERAPY, MEN (TRT)
| Search term | Searches / mo | Competition | Top-of-page bid |
|---|
| buy testosterone cypionate | 1,900 | Low | $3.09 – $10.59 |
| online testosterone prescription | 1,600 | High | $7.38 – $27.32 |
| online trt prescription | 880 | High | $8.65 – $28.42 |
| enclomiphene buy online +336% YoY | 390 | High | $2.54 – $9.00 |
Read: deep volume, low-cost clicks, and enclomiphene interest up 336% in a year. The men’s side of the hormone door is just as open.
NAD+ & WELLNESS
| Search term | Searches / mo | Competition | Top-of-page bid |
|---|
| nad injection | 74,000 | High | $2.63 – $10.14 |
| nad+ injections | 27,100 | High | $3.10 – $12.69 |
| benefits of nad+ | 22,200 | High | $0.09 – $3.02 |
| nad iv therapy | 14,800 | High | $1.58 – $5.93 |
| nad shot | 12,100 | High | $2.32 – $8.18 |
Read: 74,000 monthly searches at $2.63 entry clicks. This is the widest, cheapest door on the board, and it is included in every build.
THE HRT INFLECTION, IN THREE NUMBERS
+311%
US search growth for "perimenopause" over five years
Ahrefs, June 2021 to June 2026
Nov 2025
FDA removed the black box warning from estrogen HRT. Prescribing has more than doubled.
FDA and Truveta Research
27% → 5%
US postmenopausal HRT use, 1999 vs 2020. The white space is structural.
AARP and NIH published data
READ THE SOURCES YOURSELF, BY VERTICAL
GLP-1 & Weight Loss2 sources ▾
Peptides2 sources ▾
Hormones & Menopause13 sources ▾
Telehealth, The Macro1 source ▾
All figures above are publicly reported third-party estimates and projections about total markets, cited from bank research desks, market research firms, and agency benchmarks. They describe the market, not any individual business. GrowPro makes no income, earnings, or performance claims of any kind. Verify any figure independently; we encourage it.
